Anticipation builds as the market experiences a lull, creating the perfect atmosphere for strategic positioning. During these calmer moments, savvy traders are Anticipation builds as the market experiences a lull, creating the perfect atmosphere for strategic positioning. During these calmer moments, savvy traders are

The Quiet Phase Before the Next Cycle How Smart Traders Prepare

2026/01/27 20:06
3 min read

Anticipation builds as the market experiences a lull, creating the perfect atmosphere for strategic positioning. During these calmer moments, savvy traders are busy researching and identifying potential breakout coins. The article delves into the meticulous preparations and uncovering of promising assets ready to surge in the next cycle. Discover which cryptocurrencies are poised for growth.

BNB Price Fluctuates Within Range, Aiming for Further Upside

Source: tradingview

BNB trades between $836 and $913, showing mixed emotions in the market. While the coin recently dipped 4.75% over the past week, it gained nearly 4% over the last month and over 10% in the past six months. The next challenge lies at the $961 resistance level, with potential to climb to $1,038 if momentum builds. That could mean a rise of around 13% to 24% from current levels. Technical indicators like the RSI and moving averages suggest neutrality, yet slight bullish tilt. Holding ground above $807 offers hope for upward movement, catching investor eyes on this volatile yet promising path.

Stellar (XLM) Shows Potential Despite Recent Dips

Source: tradingview 

Stellar (XLM) is trading in the twenty-cent range, close to its ten-day average. It's facing resistance just above the twenty-cent mark but holds support at nineteen cents. Over the past week and month, XLM has dipped but it hasn't fallen below recent support. The coin's RSI suggests it's neither overbought nor oversold, hinting at potential stability. If it climbs past the first resistance level, XLM might aim for a twenty-five cent mark. This would represent a potential jump of over ten percent from its current standing. Despite recent declines, the figures suggest XLM could recover and grow if it breaks resistance barriers.

Mantle (MNT) Shows Stability with Room to Grow

Source: tradingview 

Mantle's price dances between 81 cents and 92 cents. While it's been a rough month with an 18% dip, the last half year tells a brighter story, boasting nearly a 16% gain. The price finds back-up at around 77 cents, while facing a hurdle at 98 cents. If momentum builds, breaking this could push Mantle much closer to the dollar mark at roughly $1.09. This potential rise reflects about a 25% increase from current levels. The coin's relative strength is balanced for now, with key indicators suggesting room for upward movement. Eyes are on whether Mantle can harness this to push higher in the coming days and weeks.

Algorand (ALGO) Looks to Bounce Back Despite Recent Slide

Source: tradingview 

Algorand (ALGO) is currently trading between eleven and twelve cents, showing little movement. It's been a tough six months, with the price dropping over fifty percent. However, it's near an important support level of eleven cents and could aim for a resistance level at thirteen cents or even fourteen cents. If it moves to fourteen cents, that's a potential rise of over twenty percent from its current range. The Relative Strength Index shows it’s not overbought, which hints at room for growth. While recent changes have been small, the stable moving averages suggest it might be ready to break its stagnation.

Conclusion

Smart traders are making the most of this calm period by focusing on different coins. BNB, XLM, MNT, and ALGO are among those getting attention. By analyzing current trends and positioning carefully, traders might better navigate the market's next phase. Balancing portfolios with these coins could offer advantages as conditions evolve.

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26